🇺🇸 FDA
Pipeline program

Entinostat

HCRN GU17-289

Phase 2 small_molecule active

Quick answer

Entinostat for Renal Cell Carcinoma is a Phase 2 program (small_molecule) at Syndax Pharmaceuticals Inc with 2 ClinicalTrials.gov record(s).

Program details

Company
Syndax Pharmaceuticals Inc
Indication
Renal Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials